Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Net Income (2016 - 2025)

Aptevo Therapeutics' Net Income history spans 10 years, with the latest figure at -$7.6 million for Q3 2025.

  • For Q3 2025, Net Income changed N/A year-over-year to -$7.6 million; the TTM value through Sep 2025 reached -$20.3 million, down 7033.79%, while the annual FY2023 figure was $1.2 million, 22.31% up from the prior year.
  • Net Income for Q3 2025 was -$7.6 million at Aptevo Therapeutics, down from -$6.2 million in the prior quarter.
  • Across five years, Net Income topped out at $946000.0 in Q1 2023 and bottomed at -$7.6 million in Q3 2025.
  • The 4-year median for Net Income is $165000.0 (2022), against an average of -$1.3 million.
  • The largest annual shift saw Net Income plummeted 96.79% in 2021 before it skyrocketed 431.46% in 2023.
  • A 4-year view of Net Income shows it stood at $325000.0 in 2021, then skyrocketed by 60.31% to $521000.0 in 2022, then crashed by 43.76% to $293000.0 in 2023, then tumbled by 2697.27% to -$7.6 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Net Income are -$7.6 million (Q3 2025), -$6.2 million (Q2 2025), and -$6.5 million (Q1 2025).